N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
申请人:Rodgers James D.
公开号:US20100298334A1
公开(公告)日:2010-11-25
The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I:
which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
[EN] SYNTHESIS OF FAVIPIRAVIR<br/>[FR] SYNTHÈSE DE FAVIPIRAVIR
申请人:OPTIMUS DRUGS P LTD
公开号:WO2022009036A1
公开(公告)日:2022-01-13
The present invention relates to 6-Fluoro-3-hydroxypyrazine-2-carbonitrile ammonia salt and to an improved and commercially viable process for preparation of Favipiravir using 6-fluoro-3-hydroxypyrazine-2-carbonitrile ammonia salt.
[EN] INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉASES À CYSTÉINE ET LEURS PROCÉDÉS D'UTILISATION
申请人:PARDES BIOSCIENCES INC
公开号:WO2021212039A1
公开(公告)日:2021-10-21
The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.